| |
Oxford
BioMedica (LSE: OXB) is a biopharmaceutical
company specialising in the development
of gene-based products for a range of unmet
medical needs with an emphasis on new cancer
products, which combine novel mechanisms
of action with very low side effects, and
innovative neurotherapy products, which
address large and, in several areas, untapped
markets. The products are all protected
by multiple patents comprising a total intellectual
property portfolio of some 69 patent families,
which represents one of the broadest patent
estates in the field.
In
addition to its technical research skill-base,
Oxford BioMedica has in-house clinical,
regulatory and manufacturing know-how. The
development pipeline includes two novel
anti-cancer products in clinical trials
and a gene-based treatment for Parkinson's
disease, which is in late preclinical studies.
Oxford
BioMedica has a wholly owned subsidiary
in San Diego, USA. Oxford BioMedica has
corporate collaborations with Wyeth, Intervet,
Amersham, Arius Research, Kiadis and Viragen. |
